Journal of the American Chemical Society
ARTICLE
Triazole 23. Purification by silica gel column chromatography
(5 then 10% MeOH in CH2Cl2) gave 23 as a colorless oil (25.1 mg,
87%). 1H NMR (300 MHz, CD3OD): δ 1.34-1.45 (m, 2H, CHCH2-
CH2), 1.52-1.76 (m, 4H, CHCH2CH2CH2), 2.15-2.21 (m, 2H,
CH2CdO), 2.64-2.69 (m, 1H, CHHS), 2.85-3.74 (m, 26H, CHHS,
9 ꢀ CH2O, 2 ꢀ CH2NH, CH2CHO, CHS), 3.83-4.06 (m, 4H, 2 ꢀ
CH2O), 4.21-4.28 (m, 1H, CHNH), 4.41-4.47 (m, 1H, CHNH),
4.55-4.61 (m, 2H, CH2-triazole), 5.89-6.17 (m, 1H, CH2CHO),
6.83-6.88 (m, 2H, aromH), 7.15-7.65 (m, 10H, aromH), 8.01 (s, 1H,
CHdN). MS (MALDI-ToF): 981.4092 (C46H62N8O11SNa (M þ
Naþ) requires 981.4157).
Triazole 24. Purification by silica gel column chromatography (3%
MeOH in CH2Cl2) gave 24 as a yellow amorphous solid (22 mg, 73%).
1H NMR (300 MHz, CDCl3): δ 1.80-2.02 (m, 4H, 2 ꢀ NCH2-
CH2CH2), 2.66-2.86 (m, 4H, 2 ꢀ NCH2CH2CH2), 3.01-4.12 (m,
32H, 2 ꢀ NCH2CH2CH2, 11 ꢀ CH2O, 2 ꢀ CH2NH, CH2CHO),
4.37-4.61 (m, 2H, CH2-triazole), 5.34-6.49 (m, 2H, CH2CHO,
NH), 6.73-6.82 (m, 2H, aromH), 6.93-7.60 (m, 11H, aromH), 7.92-
8.10 (m, 1H, NH), 8.56-8.68 (m, 1H, CHdN), 9.01-9.25 (m, 1H,
CH-vinyl). MS (MALDI-ToF): 1022.4133 (C54H61N7O12Na (M þ
Naþ) requires 1022.4270).
kinetic studies. This material is available free of charge via the
’ AUTHOR INFORMATION
Corresponding Author
’ ACKNOWLEDGMENT
This research was supported by the National Cancer Institute
of the U.S. National Institutes of Health (R01 CA88986, G.-J.B.),
the National Science Foundation Plant Genome Program (IOS-
0923992, G.-J.B.), the National Science Foundation (CHE-
0449478, V.V.P.), and the Georgia Cancer Coalition (V.V.P.).
’ REFERENCES
(1) (a) Wittig, G.; Krebs, A. Chem. Ber. 1961, 94, 3260–3275. (b)
Jewett, J. C.; Bertozzi, C. R. Chem. Soc. Rev. 2010, 39, 1272–1279. (c)
Debets, M. F.; van der Doelen, C. W. J.; Rutjes, F. P. J. T.; van Delft, F. L.
ChemBioChem 2010, 11, 1168–1184. (d) Becer, C. R.; Hoogenboom,
R.; Schubert, U. Angew. Chem., Int. Ed. 2009, 48, 4900–4908.
(2) Agard, N. J.; Baskin, J. M.; Prescher, J. A.; Lo, A.; Bertozzi, C. R.
ACS Chem. Biol. 2006, 1, 644–648.
(3) (a) Link, A. J.; Vink, M. K. S.; Agard, N. J.; Prescher, J. A.;
Bertozzi, C. R.; Tirrell, D. A. Proc. Natl. Acad. Sci. U.S.A. 2006, 103,
10180–10185. (b) Tanrikulu, I. C.; Schmitt, E.; Mechulam, Y.; Goddard,
W. A., III; Tirrell, D. A. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 15285–
15290.
(4) (a) Fernꢀandez-Suꢀarez, M.; Baruah, H.; Martínez-Hernꢀandez, L.;
Xie, K. T.; Baskin, J. M.; Bertozzi, C. R.; Ting, A. Y. Nat. Biotechnol. 2007,
25, 1483–1487. (b) Neef, A. B.; Schultz, C. Angew. Chem., Int. Ed. 2009,
48, 1498–1500.
(5) Nessen, M. A.; Kramer, G.; Back, J. W.; Baskin, J. M.; Smeenk,
L. E. J.; de Koning, L. J.; van Maarseveen, J. H.; de Jong, L.; Bertozzi,
C. R.; Hiemstra, H.; de Koster, C. G. J. Proteome Res. 2009, 8, 3702–
3711.
General Procedure for SPANOC between Triazoles 23 or
24 and Glycodendrimer 25. To a stirred solution of DIBO-
glycodendrimer 25 (20.5 mg, 5.2 μmol) and oxime 23 or 24 (5.2 μmol)
in MeOH/CH2Cl2 (4/1, v/v, 1.2 mL) was added a solution of BAIB (1.8
mg, 5.7 μmol) in MeOH (0.18 mL), and the reaction mixture was stirred
for 30 min. The solvent was evaporated, and the residue was purified by
RP-HPLC. Appropriate fractions were combined and lyophilized.
Glycodendrimer-Biotin Conjugate 26. After RP-HPLC pur-
ification (0-5 min 0% B, 5-40 min gradient of 0-100% B, t = 29.4
min) and lyophilization, 26 was obtained as a white powder (14.0 mg,
1
55%). H NMR (500 MHz, D2O): δ 0.88-1.22 (m, 23H, 7 ꢀ CH3,
CHCH2CH2), 1.32-1.63 (m, 4H, CHCH2CH2CH2), 1.95-2.22 (m,
18H, 8 ꢀ CH2CH2CH2-triazole, CH2CdO), 2.48-2.80 (m, 17H,
CHHS, 8 ꢀ CH2CH2-triazole), 2.80-3.02 (m, 17H, CHHS, 8 ꢀ
CH2CH2-triazole), 3.08-3.95 (m, 107H, 2ꢀCH2CHO, 4 ꢀ CH2NH,
15 ꢀ CH2O, 8 ꢀ CH-2gal, 8 ꢀ CH-3gal, 8 ꢀ CH-5gal, 8 ꢀ CH2-6gal, 8 ꢀ
CH-4gal, 8 ꢀ CH2CH2CH2-triazole, CHS), 3.99-4.55 (m, 56H, 9 ꢀ
CH2-triazole, 14 ꢀ OCH2, 2 ꢀ CHNH, 8 ꢀ CH-1gal), 5.55-6.15 (m,
2H, 2 ꢀ CH2CHO), 6.33-7.60 (m, 20H, aromH), 7.87 (s, 8H, 8 ꢀ
CHtriazole). MS (MALDI-ToF): 4933.4 (C218H310N34O92SNa (M þ
Naþ) requires 4933.0).
(6) Kele, P.; Mez€o, G.; Achats, F.; Wolfbeis, O. S. Angew. Chem., Int.
Ed. 2009, 48, 344–347.
(7) (a) Jayaprakash, K. N.; Pend, C. G.; Butler, D.; Varghese, J. P.;
Maier, M. A.; Rajeev, K. G.; Manoharan, M. Org. Lett. 2010, 12, 5410–
5413. (b) van Delft, P.; Meeuwenoord, N. J.; Hoogendoorn, S.;
Dinkelaar, J.; Overkleeft, H. S.; van der Marel, G. A.; Filippov, D. V.
Org. Lett. 2010, 12, 5486–5489.
Glycodendrimer-Coumarin Conjugate 27. After RP-HPLC
purification (0-5 min 0% B, 5-10 min gradient of 0-40% B, 10-
30 min gradient of 40-60% B, t = 25.3 min) and lyophilization, 27 was
obtained as a yellow powder (15.1 mg, 61%). 1H NMR (500 MHz, D2O:
CD3CN, 1:1, v/v) δ 0.99-1.20 (m, 21H, 7 ꢀ CH3), 1.65-1.81 (m, 4H,
2 ꢀ NCH2CH2CH2), 1.99-2.08 (m, 16H, 8 ꢀ CH2CH2CH2-triazole),
2.59-2.62 (m, 20H, 2 ꢀ NCH2CH2CH2, 8 ꢀ CH2CH2-triazole), 2.84
(t, J = 7.3 Hz, 16H, 8 ꢀ CH2CH2-triazole), 3.10-3.94 (m, 110H, 2 ꢀ
CH2CHO, 4 ꢀ CH2NH, 15 ꢀ CH2O, 2 ꢀ NCH2CH2CH2, 8 ꢀ CH-2gal,
8 ꢀ CH-3gal, 8 ꢀ CH-5gal, 8 ꢀ CH2-6gal, 8 ꢀ CH-4gal, 8 ꢀ CH2CH2-
CH2-triazole), 3.94-4.25 (m, 36H, 14 ꢀ OCH2, 8 ꢀ CH-1gal), 4.25-
4.45 (m, 18H, 9 ꢀ CH2-triazole), 5.41-6.19 (m, 2H, 2 ꢀ CH2CHO),
6.58-7.51 (m, 21H, aromH), 7.64 (s, 8H, 8 ꢀ CHtriazole), 8.36-9.12 (m,
1H, CH-vinyl). MS (MALDI-ToF): 4972.8 (C224H309N33O93Na (M þ
Naþ) requires 4974.0).
(8) Wilson, J. T.; Krishnamurthy, V. R.; Cui, W.; Qu, Z.; Chaikof,
E. L. J. Am. Chem. Soc. 2009, 131, 18228–18229.
(9) Johnson, J. A.; Baskin, J. M.; Bertozzi, C. R.; Koberstein, J. T.;
Turro, N. J. Chem. Commun. 2008, 3064–3066.
(10) (a) Ornelas, C.; Broichhagen, J.; Weck, M. J. Am. Chem. Soc.
2010, 132, 3923–3931. (b) Ledin, P. A.; Friscourt, F.; Guo, J.; Boons,
G.-J. Chem.-Eur. J. 2010, in press (DOI: 10.1002/chem.201002052).
(11) Lallana, E.; Fernandez-Megia, E.; Riguera, R. J. Am. Chem. Soc.
2009, 131, 5748–5750.
(12) Orski, S. V.; Poloukhtine, A. A.; Arumugam, S.; Mao, L.; Popik,
V. V.; Locklin, J. J. Am. Chem. Soc. 2010, 132, 11024–11026.
(13) (a) Ess, D. H.; Jones, G. O.; Houk, K. N. Org. Lett. 2008, 10,
1633–1636. (b) Bach, R. D. J. Am. Chem. Soc. 2009, 131, 5233–5243. (c)
Schoenebeck, F.; Ess, D. H.; Jones, G. O.; Houk, K. N. J. Am. Chem. Soc.
2009, 131, 8121–8133. (d) Chenoweth, K.; Chenoweth, D.; Goddard,
W. A., III. Org. Biomol. Chem. 2009, 7, 5255–5258.
(14) (a) Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; Agard, N. J.;
Chang, P. V.; Miller, I. A.; Lo, A.; Codelli, J. A.; Bertozzi, C. R. Proc. Natl.
Acad. Sci. U.S.A. 2007, 104, 16793–16797. (b) Codelli, J. A.; Baskin,
J. M.; Agard, N. J.; Bertozzi, C. R. J. Am. Chem. Soc. 2008, 130, 11486–
11493.
’ ASSOCIATED CONTENT
S
Supporting Information. Synthesis of oximes 14a-f,
b
imidoyl chlorides 5a-f, azido-oxime linker 18, DIBO-galactose
19, amino-PEG-coumarin 33, and DIBO-glycodendron 25.
Spectral data of new compounds, and detailed reaction profiles in
(15) Ning, X.; Guo, J.; Wolfert, M. A.; Boons, G.-J. Angew. Chem., Int.
Ed. 2008, 47, 2253–2255.
956
dx.doi.org/10.1021/ja1081519 |J. Am. Chem. Soc. 2011, 133, 949–957